Q1 Earnings Forecast for NAMS Issued By HC Wainwright

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of NewAmsterdam Pharma in a research note issued to investors on Thursday, February 19th. HC Wainwright analyst L. Egana-Gorrono forecasts that the company will post earnings of ($0.35) per share for the quarter. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q2 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.35) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at $2.36 EPS, FY2028 earnings at $3.83 EPS, FY2029 earnings at $7.02 EPS and FY2030 earnings at $7.87 EPS.

Several other research analysts have also commented on the stock. Leerink Partners restated an “outperform” rating and issued a $55.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. Guggenheim lifted their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Stifel Nicolaus raised their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, The Goldman Sachs Group lifted their price objective on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research report on Tuesday, December 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $47.00.

NewAmsterdam Pharma Stock Up 2.7%

Shares of NAMS stock opened at $35.58 on Monday. The firm has a market capitalization of $4.03 billion, a price-to-earnings ratio of -20.57 and a beta of 0.06. The stock has a fifty day moving average of $33.97 and a 200 day moving average of $32.68. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently modified their holdings of NAMS. Empowered Funds LLC purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth about $85,000. XTX Topco Ltd grew its position in NewAmsterdam Pharma by 1,714.1% during the 4th quarter. XTX Topco Ltd now owns 137,492 shares of the company’s stock valued at $4,823,000 after purchasing an additional 129,913 shares during the last quarter. Virtus Investment Advisers LLC increased its stake in NewAmsterdam Pharma by 32.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company’s stock valued at $251,000 after purchasing an additional 1,731 shares in the last quarter. Twinbeech Capital LP purchased a new position in NewAmsterdam Pharma in the fourth quarter worth about $961,000. Finally, Millennium Management LLC purchased a new position in NewAmsterdam Pharma in the fourth quarter worth about $8,931,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $33.25, for a total value of $199,500.00. Following the sale, the insider directly owned 73,481 shares of the company’s stock, valued at $2,443,243.25. The trade was a 7.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 32,612 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $31.80, for a total value of $1,037,061.60. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at $774,425.40. The trade was a 57.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 298,647 shares of company stock worth $10,236,050 in the last three months. 20.84% of the stock is currently owned by insiders.

Trending Headlines about NewAmsterdam Pharma

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: HC Wainwright published a bullish note/upgrade on NAMS, reinforcing a constructive view that likely supported buying interest. NewAmsterdam Pharma (NASDAQ:NAMS) Upgraded at HC Wainwright
• Positive Sentiment: HC Wainwright’s detailed model shows a path from near‑term losses to large, positive earnings in later years (FY2026 loss narrowing, then EPS of $2.36 in FY2027, $3.83 in FY2028, $7.02 in FY2029 and $7.87 in FY2030). That multi‑year upside projection is a clear bullish catalyst for growth‑oriented investors.
• Neutral Sentiment: HC Wainwright’s near‑term quarterly estimates still show losses (Q1/Q2/Q4 2026 EPS around -$0.34 to -$0.35), so the firm’s upgrade is more about long‑term potential than immediate profit improvement.
• Negative Sentiment: Wall Street Zen lowered NAMS to a Sell, creating analyst disagreement that can increase intraday volatility and limit momentum from bullish notes. NewAmsterdam Pharma (NASDAQ:NAMS) Lowered to Sell Rating by Wall Street Zen
• Negative Sentiment: Recent reported results showed a quarterly EPS miss and almost no revenue, underscoring execution and near‑term commercial risk that could undermine enthusiasm if fundamentals don’t improve.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.